公开(公告)号：US11623929B2

公开(公告)日：2023-04-11

申请号：US17103621

申请日：2020-11-24

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Fabian Dey ,  Annick Goergler ,  Roger Norcross ,  Philipp Schmid

IPC: C07D487/10 ,  C07D519/00 ,  A61P35/00

Abstract: The present invention provides compounds and intermediates. The present invention also provides compounds which bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation. The present invention also provides compounds that may be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20230082430A1

公开(公告)日：2023-03-16

申请号：US17723199

申请日：2022-04-18

Applicant: C4 Therapeutics, Inc.

Inventor： James A. Henderson ,  Minsheng He ,  Andrew Charles Good ,  Andrew John Phillips

IPC: C07D401/04

Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

公开(公告)号：US20230019060A1

公开(公告)日：2023-01-19

申请号：US17465583

申请日：2021-09-02

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Roger Norcross ,  Fabian Dey ,  Annick Goergler ,  Eric Kusznir

IPC: C07D413/04 ,  C07D403/04 ,  C07D471/04 ,  C07D417/04

Abstract: The present invention provides heterocyclic compounds that bind to the ubiquitously expressed E3 ligase protein cereblon (CRBN) and their use for the treatment of abnormal cellular proliferation in a human or other host. The present invention also provides compounds that can be used as synthetic intermediates in the synthesis of bifunctional compounds used for targeted protein degradation.

公开(公告)号：US20220372016A1

公开(公告)日：2022-11-24

申请号：US17351935

申请日：2021-06-18

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Christopher G. Nasveschuk ,  James A. Henderson ,  Katrina L. Jackson ,  Minsheng He ,  Yanke Liang ,  Mark E. Fitzgerald ,  Victoria Garza

IPC: C07D401/14 ,  C07D401/04 ,  C07D401/10 ,  C07D239/22

Abstract: This invention provides pharmaceutical protein degraders and E3 ubiquitin ligase binders for therapeutic applications as described further herein.

公开(公告)号：US20220313827A1

公开(公告)日：2022-10-06

申请号：US17121389

申请日：2020-12-14

Applicant: C4 Therapeutics, Inc.

Inventor： Andrew J. Phillips ,  Chris G. Nasveschuk ,  James A. Henderson ,  Yanke Liang ,  Chi-li Chen ,  Martin Duplessis ,  Minsheng He ,  Kiel Lazarski

IPC: A61K47/54 ,  C07D401/14 ,  C07D495/14 ,  C07D487/04 ,  C07D471/04 ,  C07D405/14 ,  C07D401/04 ,  C07D413/12 ,  C07D211/88 ,  C07D401/12 ,  C07D413/04 ,  A61K31/45 ,  A61K31/454 ,  A61K31/4545 ,  A61K31/4709 ,  A61K31/513

Abstract: This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

公开(公告)号：US11407732B1

公开(公告)日：2022-08-09

申请号：US17498617

申请日：2021-10-11

Applicant: C4 Therapeutics, Inc.

Inventor： James A. Henderson ,  Minsheng He ,  Andrew Charles Good ,  Andrew John Phillips

IPC: C07D401/04

Abstract: Tricyclic cereblon binders for the degradation of Ikaros or Aiolos by the ubiquitin proteasome pathway for therapeutic applications are described.

公开(公告)号：US20210198256A1

公开(公告)日：2021-07-01

申请号：US17192634

申请日：2021-03-04

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Rhamy Zeid

IPC: C07D471/04 ,  C07D401/14 ,  C07D417/14

Abstract: Compounds that degrade BRD9 or MTH1 via the ubiquitin proteasome pathway in a subject in need thereof for therapeutic applications are provided. The compounds provided have an E3 Ubiquitin Ligase targeting moiety (Degron) that is linked to a Targeting Ligand for BRD9 or MTH1.

公开(公告)号：US20240245677A1

公开(公告)日：2024-07-25

申请号：US18600097

申请日：2024-03-08

Applicant: C4 THERAPEUTICS, INC.

Inventor： Katrina L. Jackson ,  Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap ,  Minsheng He ,  Robert T. Yu ,  Matthew J. Schnaderbeck ,  Kathleen Neville ,  Siyi Jiang ,  Meiqi Li ,  Qianwei Liu ,  Manjie Zheng ,  Jia Li ,  Liwei Zhang

IPC: A61K31/496 ,  A61P35/00

CPC classification number: A61K31/496 ,  A61P35/00

Abstract: Selected BRD9 protein degradation compounds and morphic forms thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.

公开(公告)号：US20240158418A1

公开(公告)日：2024-05-16

申请号：US18516589

申请日：2023-11-21

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Martin Duplessis ,  Jae Young Ahn ,  Alexander W. Hird ,  Ryan E. Michael ,  Kiel Lazarski ,  Yanke Liang ,  Georg Jaeschke ,  Antonio Ricci ,  Annick Goergler ,  Daniel Rueher

IPC: C07D519/00 ,  A61P35/04

CPC classification number: C07D519/00 ,  A61P35/04

Abstract: The invention provides for the treatment of mutant epidermal growth factor receptor (EGFR) mediated cancer that has metastasized to the brain or other area of the central nervous system with a compound that degrades a mutant form of EGFR via the ubiquitination of the EGFR protein and subsequent proteasomal degradation. The invention also provides advantageous drug combinations for the treatment of such cancer that include a compound herein that degrades a mutant form of EGFR in combination with a second anti-cancer agent.

公开(公告)号：US20240051953A1

公开(公告)日：2024-02-15

申请号：US17965569

申请日：2022-10-13

Applicant: C4 Therapeutics, Inc.

Inventor： Christopher G. Nasveschuk ,  Rhamy Zeid ,  Ning Yin ,  Katrina L. Jackson ,  Gesine Kerstin Veits ,  Moses Moustakim ,  Jeremy L. Yap

IPC: C07D471/04 ,  C07D401/14 ,  A61P35/00

CPC classification number: C07D471/04 ,  A61P35/00 ,  C07D401/14

Abstract: BRD9 protein degradation compounds or pharmaceutically acceptable salts thereof are provided for the treatment of disorders mediated by BRD9, including but not limited to abnormal cellular proliferation.